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Streszczenie
Wstęp Uważa się, że dysfunkcja śródbłonka odgrywa
kluczową rolę w rozwoju miażdżycy i powstawaniu
powikłań układu sercowo-naczyniowego w nadciś-
nieniu tętniczym.
Materiał i metody Celem oceny dysfunkcji śródbłonka
u nieleczonych chorych z pierwotnym nadciśnie-
niem tętniczym, bez cukrzycy, z prawidłowym kli-
rensem kreatyniny zbadaliśmy 29 ambulatoryjnych
pacjentów (13K/16M; wiek: 41,17 ± 11,95) w porów-
naniu z grupą 14 zdrowych ochotników (7K/7M),
zgodnych wiekowo. W obu grupach we krwi żylnej
na czczo oznaczono: HbA1c, całkowitą homocyste-
inę, kwas moczowy, insulinę, glukozę, vWF:Ag, TM,
PAI-1, E-selektyny. Obliczono HOMA-IR. W 24-go-
dzinnej zbiórce moczu oznaczono mikroalbuminu-
rię (MA) i N-acetylo-b-D-glukozaminidazę (NAG).
Wyniki Chorzy z nadciśnieniem prezentowali wy-
ższe wartości BMI, WHR, MAP, PP, cechowali się
insulinoopornością i wyższym stężeniem kwasu mo-
czowego. Grupy nie różniły się pod względem MA
i vWF:Ag. Chorzy mieli wyższe wartości PAI-1
i NAG niż kontrola. Jedynie u chorych stwierdzono
dodatnie korelacje liniowe: PP vs. MAlog10, PAI-1 vs.
MAlog10, PAI-1 vs. kwas moczowy, PAI-1 vs. BMI,
PAI-1 vs. WHR, WHR vs. kwas moczowy, BMI vs.
HOMA-IR.
Wnioski Nasze dane mogą wskazywać, że we wcze-
snych etapach nadciśnienia tętniczego, chorzy z in-
sulinoopornością cechują się zwiększonym ryzykiem
sercowo-naczyniowym związanym z uogólnioną
miażdżycą, stanem prozakrzepowym i zwiększoną
sztywnością tętnic. Kwas moczowy prawdopodobnie
wpływa na śródbłonek poprzez mediowany przez
PAI-1 mechanizm, który nie jest jasny. Odbiciem
tego faktu jest podwyższona wartość PP wynikająca
ze zmniejszenia podatności tętnic. Zwiększone wy-
dalanie NAG z moczem u chorych w obliczu nor-
moalbuminurii może wskazywać na uszkodzenie
śródmiąższu nerek, które wyprzedza uszkodzenie
kłębuszka i jest istotne dla dalszego rokowania.
słowa kluczowe: śródbłonek, nadciśnienie,
kwas moczowy, nerka, metabolizm
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Introduction
There is a potential relationship between endo-
thelial dysfunction (ED) and non-diabetic renal dise-
ase in essential arterial hypertension. ED is now re-
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cognised as a key factor in the onset and progression
of atherosclerosis, which results in fatal cardiovascu-
lar events such as stroke and myocardial infarction.
The balance of substances derived from the endothe-
lium determines vascular tone and permeability and
affects coagulation, inflammation, proliferation, ad-
hesion and platelet and leucocyte function. Nume-
rous traditional and non-traditional risk factors are
involved in this process, although arterial hyperten-
sion with elements of insulin resistance syndrome is
crucial [1]. Growing attention is also being paid to
microcirculation and capillary rarefaction, which
may become a new target for treatment.
Micro-albuminuria (MA) is not only recognised
as a risk factor of renal damage but is also treated as
a marker of generalised endothelial malfunction [2, 3].
MA is an independent predictor of cardiovascular
disease and death, according to JNC VII, and often
coexists with composed metabolic disturbances such
as insulin resistance [4], although MA is not a deter-
minant of insulin resistance [5].
MA is also common in the non-diabetic, non-hy-
pertensive healthy population and is an independent
indicator of cardiovascular risk and cardiovascular
morbidity in this group [6, 7]. It seems that there is
a continuous relationship between urine albumin
excretion and all-cause and cardiovascular mortality
in the general population (EPIC-Norfolk Study).
Homocysteine lowering therapy with folic acid de-
creases MA. ED may precede and predict MA [8].
The role of uric acid in vascular damage is still
a matter of discussion [9]. However, a pharmacolo-
gical decrease in uric acid level does not result in
increased life expectancy [10].
On the other hand, the elevated pulsative compo-
nent of blood pressure, pulse pressure (PP) value,
defined as the difference between systolic and diasto-
lic blood pressure, is closely related to a high risk of
cardiovascular death or it is caused by a decrease of
compliance in the large arteries and an elevation of
blood wave reflection from the peripheral arteries,
increasing arterial stiffness [11, 12].
Materials and methods
The aim of our study was to evaluate generalised
endothelial dysfunction in non-diabetic untreated es-
sential hypertensives with a normal creatinine cle-
arance range. We therefore examined 29 ambulatory pa-
tients (13F/16M; age: 41.17 ± 11.95) and compared them
with 14 healthy controls (7F/7M), matched for age.
We measured BMI and WHR using routine proce-
dures. We obtained SBP, DBP, PP and MAP using
a standardised mercury sphygmomanometer and the
Korotkoff method with the patient in sitting position
after 5 minutes’ rest. Fasting venous blood was with-
drawn for: HbA1c, total homocysteine, uric acid, insu-
lin and glucose, vWF:Ag, TM, PAI-1 and E-selectins
in both groups. The insulin resistance index (HOMA-
IR) was calculated using Matthews’ formula. The 24-h
urine was collected for albumin and N-acetyl-b-D-glu-
cosaminidase (NAG) urine excretion in both groups.
The results are expressed as a mean ± standard
deviation when normal distribution is found. Data
without normal distribution are presented as median
and range. The Statistica 5 program was used to per-
form the statistical analysis. We considered p < 0.05
statistically significant and the SN abbreviation was
used to represent no significance. The significance of
differences between means of measurements for the
two groups was determined by Student’s test or the
Cochran-Cox test after an analysis of variances by
the Fisher test. The Mann-Whitney U non-parame-
tric test was also used for unpaired data without nor-
mal distribution. Pearson’s correlation co-efficients
were performed to assess linear relationship.
The study protocol was approved by the Ethics
Committee at The Ludwik Rydygier Medical Uni-
versity in Bydgoszcz, Poland. Written informed
consent was obtained from all study participants.
Results
The results are presented in table I.
Discussion
Our study has some limitations and may be un-
derpowered as a result of the low number of patients.
Our patients had higher BMI and WHR values than
the controls and they revealed some metabolic
disturbances such as insulin resistance (elevated
HOMA-IR) and hyperuricaemia in comparison with
the healthy volunteers. There was a linear correlation
between BMI and HOMA-IR (r = 0.64; p < 0.01)
in hypertensives only. The groups did not differ as
regards vWF:Ag level and the albuminuria was the
same in both hypertensives and controls.
This suggests no endothelial dysfunction in the
hypertensives. In view of the similarity in the amo-
unt of albumin excretion in the hypertensives and
the normotensive controls, the mechanisms underly-
ing this process must be different. This assumption
is based on the following correlations, which were
found in the hypertensives only:
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PP vs. MAlog10 (r = 0.48; p < 0.05), PAI-1 vs. MA-
log10 (r = 0.39; p < 0.05), PAI-1 vs. uric acid (r = 0.56;
p < 0.01), PAI-1 vs. BMI (r = 0.57; p < 0.01), PAI-1
vs. WHR (r = 0.41; p < 0.01), WHR vs. uric acid
(r = 0.46; p < 0.05).
These correlations suggest that it is the quantity
rather than quality of metabolic disturbances in hy-
pertensives which drive unfavourable events in the en-
dothelium. This study suggests that a role is played by
PAI-1 in the association between metabolic processes
and the function of the cardiovascular system in hy-
pertensives. Nowadays PAI-1 is known as a direct and
indirect profibrotic intravascular factor interacting
through the inhibition of tissue-type plasminogen
activator (tPA) and urokinase-type plasminogen acti-
vator (uPA). The activation of the renin-angiotensin-
aldosteron system (both angiotensin II and aldostero-
ne) directly induces undesirable expression of PAI-1
[13, 14]. Consequently PAI-1 may indirectly enhance
arterial stiffness causing higher pulse pressure.
Nevertheless, hypertensives had higher PAI-1
levels than the controls, suggesting the undesirable
effect of the prothrombotic state of the fibrinolytic
system, which may reduce the efficiency of vascular
and tissue remodelling.
The association between hyperuricaemia and va-
scular damage is a well-known fact but the question
of what is meant by its primary and secondary effects
remains unresolved.
It is proposed that uric acid is elevated in hyper-
tensives owing to increased renal proximal tubular
reabsorption (as a result of hyperinsulinaemia), de-
creased renal blood flow and local renal ischemia
arising from increased sympathetic activity. Howe-
ver, it is possible that uric acid is also a pathogenic
factor with broad biological actions (pro-inflamma-
tory and with pro-oxidative and anti-oxidative pro-
perties depending on conditions) with regard to en-
dothelial damage in hypertension and cardiovascu-
lar disease [9]. There is a reciprocal pattern of uric
acid and nitric oxide levels during the day, which
may be a reflection of ED [15].
Hyperuricaemia may lead to intrarenal vascular
injury and may be a mediator of renal disease in rats
[16]. Experimental hyperuricaemia in rats causes hy-
pertension and stimulates vascular smooth muscle
cell proliferation [17]. These observations provide
new in sights into hyperuricaemia in humans. Our
study was not planned to determine the effect of
a lowering of uric acid on PAI-1 levels.
Table I. Baseline characteristics of hypertensives and healthy controls
Tabela I. Wstępna charakterystyka pacjentów
Parameter Hypertensives Controls p
BMI 28.83 ± 4.45 23.07± 2.43  < 0.01
WHR 0.91 ± 0.09 0.83 ± 0.10  < 0.01
SBP [mm Hg] 164 ± 16 105 ± 7  < 0.01
DBP [mm Hg] 115 ± 14 69 ± 9  < 0.01
PP [mm Hg] 59 ± 12 46 ± 7 < 0.001
MAP [mm Hg] 125 ± 9 84 ± 10 < 0.001
HbA1c (%) 5.94 ± 0.55 5.61 ± 0.76 NS
Uric acid [mmol/L] 370,7 ± 105 263,6 ± 70.8  < 0.01
Total homocysteine [mmol/L] 9.71 ± 2.68 8.39 ± 2.55 NS
HOMA-IR 3.27 ± 1.71 1.59 ± 0.53 < 0.001
PAI-1 [ng/mL] 39.02 ± 22.12 25.26 ± 16.84  < 0.05
vWF:Ag (%) 227.98 ± 133.97 244.10 ± 121.32 NS
TM [U/mL] 3.60 ± 1.05 3.59 ± 0.93 NS
E-selectin [ng/mL] 62.68 ± 39.71 39.66 ± 11.48  < 0.01
Creatinine clearance   [mL/min/1,73m2] 99.04 ± 30.29 110.36 ± 39.84 NS
NAG [U/L/g creat] 1.95 (0.94–10.60) 1.28 (0,25–5.89)  < 0.05
2.83 ± 2.11  1.82 ± 1.46
Albuminuria [mg/24 h] 13.20 (4.50–75.20) 10.53 (6.00–57.63) NS
16.69 ± 13.06  16.18 ± 15.13
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Both positive correlations between PAI-1 and uric
acid, PAI-1 and MAlog10 may suggest that in the early
stage of untreated essential hypertension uric acid is
able to affect the endothelium through a PAI-1 me-
diated mechanism. A reflection of this is the incre-
ased PP which results from higher arterial stiffness.
No significant statistical correlation was found be-
tween PP and the other factors measured either in
the hypertensives or in the controls.
Our data may suggest that in the very early stages
of essential arterial hypertension the hypertensives
with probable insulin resistance are at high risk of
serious cardiovascular complications related to diffu-
se atherosclerosis, a prothrombotic state and elevated
arterial stiffness. Hypertensives had higher NAG uri-
ne excretion than the controls while showing no en-
dothelial dysfunction (estimated with MA) and nor-
mal creatinine clearance. This may indicate the early
renal tubulo-interstitium tissue damage resulting
from probable intrarenal vessel damage due to hype-
ruricaemia in the face of elevated PAI-1 which pre-
cedes glomerular injury and is important for the fu-
ture clinical prognosis. No linear correlation was fo-
und between NAG urine excretion and homocyste-
ine, MA, PP, HOMA, PAI-1, BMI, WHR, insulin.
Nor was there any correlation between NAG excre-
tion and MAP, which we found in a similar group of
untreated hypertensives [18]. Our results, although
obtained from a relatively small group of patients,
are consistent with the data of Tsioufis and Viazzi
[11], who proposed that PP may be a marker of prec-
linical vascular injury in young hypertensive patients.
Summary
Background Attention is increasingly being paid to en-
dothelial dysfunction (ED) as a key aspect of atherosclero-
sis and target organ damage in arterial hypertension.
Material and methods In order to evaluate generalised
ED in non-diabetic untreated essential hypertensives with
normal creatinine clearance we examined 29 ambulatory
patients (13F/16M; age: 41.17 ± 11.95) and compared
them with 14 healthy controls (7F/7M) matched for age.
Fasting blood was withdrawn for the following: HbA1c,
total homocysteine, uric acid, insulin, glucose, vWF:Ag, TM,
PAI-1 and E-selectins in both groups. HOMA-IR was
calculated. 24-h urine was collected for microalbuminuria
(MA) and N-acetyl-ß-D-glucosaminidase (NAG) urine
excretion.
Results The hypertensives had higher BMI, WHR, MAP
and PP and were insulin resistant. They revealed hyperu-
ricaemia. No difference was found in MA and vWF:Ag.
The hypertensives also had higher PAI-1 levels and NAG
excretion than the controls. The only positive linear corre-
lations found in the hypertensives were the following: PP
vs. MAlog10, PAI-1 vs. MAlog10, PAI-1 vs. uric acid, PAI-1 vs. BMI,
PAI-1 vs. WHR, WHR vs. uric acid, BMI vs. HOMA-IR.
Conclusion Our data may suggest that in the early stages
of essential hypertension patients with insulin resistance
are at high risk of serious cardiovascular complications re-
lated to diffuse atherosclerosis, a prothrombotic state and
elevated arterial stiffness. Uric acid is able to affect en-
dothelium through a PAI-1 mediated mechanism, which
remains unclear. This fact is reflected in the increased PP
which results from increased arterial stiffness. Higher
NAG urine excretion where there is no endothelial dys-
function may indicate the early renal tubulo-interstitium
tissue damage which precedes glomerular injury and is
important for future clinical prognosis.
key words: endothelium, hypertension, uric acid, kidney,
metabolism
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